Neglected Tropical Disease Treatment Market by Drug Type (Anthelmintics, Antiarthropodals, Antibiotics), Disease Indication (Dengue, Lymphatic Filariasis, Onchocerciasis), Route Of Administration, Treatment Approach, End User, Distribution Channel - Globa
Description
The Neglected Tropical Disease Treatment Market was valued at USD 6.40 billion in 2024 and is projected to grow to USD 6.83 billion in 2025, with a CAGR of 6.73%, reaching USD 10.79 billion by 2032.
Comprehensive contextual introduction framing the clinical, programmatic, and supply chain imperatives that define neglected tropical disease treatment today
Neglected tropical diseases remain stubbornly prevalent across many low-resource settings, demanding renewed strategic focus from health systems, funders, and manufacturers alike. This introduction frames the current treatment landscape, emphasizing the complex interplay of clinical needs, programmatic delivery, and supply chain constraints that shape patient access to essential interventions. It acknowledges the progress achieved through mass drug administration campaigns and targeted therapies while also underscoring persistent gaps in coverage, diagnostics, and sustainable manufacturing capacity.
Drawing on recent regulatory shifts, partnerships between public and private stakeholders, and evolving donor priorities, the narrative situates stakeholders at the intersection of opportunity and urgency. Consequently, health leaders must reconcile short-term operational pressures with long-term investments in local capacity building. In particular, procurement teams and program managers need evidence-based guidance that aligns clinical protocols with distribution realities, including the logistical demands of reaching remote clinics, community health centers, mobile camps, and hospital settings.
Overall, the introduction sets a pragmatic tone: it invites multidisciplinary collaboration, highlights actionable entry points for strengthening treatment delivery, and prepares readers for deeper analysis of structural shifts, tariff-driven disruptions, and segmentation-specific implications in the sections that follow
Transformative shifts in diagnostics, partnerships, regulatory harmonization, and delivery models that are redefining neglected tropical disease treatment paradigms
The treatment landscape for neglected tropical diseases is undergoing decisive transformation as new scientific, policy, and operational forces converge. Advances in diagnostics and drug development are refining treatment algorithms, while digital health tools and geospatial analytics are allowing program managers to target interventions more precisely. Simultaneously, regulatory harmonization efforts and accelerated approval pathways are reducing time to deployment for critical therapies, enabling faster translation of research into practice.
Institutional shifts are likewise reshaping funding models and partnership structures. Donor portfolios increasingly prioritize integrated health platforms that bundle NTD interventions with broader primary care services, which in turn affects procurement strategies and distribution planning. Public-private collaborations are scaling up technology transfers and local manufacturing pilots, responding to the dual pressures of supply security and cost containment. As a result, traditional models of centralized mass drug administration are adapting to incorporate more targeted therapy approaches in settings where surveillance data justify differentiated responses.
Taken together, these transformative shifts underscore a move from one-size-fits-all campaigns toward adaptive, evidence-driven programs. Stakeholders must therefore pivot to agile operational frameworks that combine clinical efficacy with resilient supply chains and community-centered delivery models to sustain long-term impact
Cumulative global supply chain and procurement consequences stemming from new tariff measures introduced in the United States and their operational ripple effects
The introduction of new tariff measures in the United States during 2025 has produced a ripple effect across global supply chains that serve neglected tropical disease treatment programs. In practical terms, higher import tariffs on pharmaceutical inputs and finished products have elevated landed costs for manufacturers and procurers that rely on transnational APIs and finished-dose manufacturing. This has prompted urgency among program managers and procurement teams to reassess sourcing strategies and to prioritize supply chain redundancy and transparency.
Consequently, manufacturers and contract production organizations are accelerating conversations around nearshoring and regional manufacturing hubs to mitigate tariff exposure and transportation bottlenecks. These shifts have direct implications for procurement timelines, as lead times lengthen when new supplier qualification and regulatory compliance processes are required. In addition, civil society organizations and humanitarian procurers face tighter budgeting constraints that complicate the planning of large-scale distribution efforts.
Moreover, the tariff environment has catalyzed a renewed emphasis on partnerships that de-risk supply continuity. Strategic responses have included coordinated pooled procurement, supplier diversification, and contractual mechanisms that share tariff-related cost volatility across stakeholders. While this restructuring introduces short-term operational friction, it also creates opportunities to build more resilient, regionally anchored manufacturing and distribution models that can sustain treatment programs under evolving trade regimes
Rich segmentation-driven insights that align disease-specific clinical needs with formulation, distribution channel capacity, end-user realities, and treatment strategies
Segment-specific analysis reveals differentiated implications across therapeutic indications, drug classes, distribution channels, end-user settings, routes of administration, and treatment approaches. Based on disease indication, the landscape varies between vector-borne viral diseases like dengue and parasitic infections such as lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma, with each disease presenting unique clinical requirements and programmatic delivery challenges. Treatment modalities diverge materially when considering drug type, where anthelmintics, antiarthropodals, antibiotics, antiprotozoals, and insecticides occupy distinct development, procurement, and storage profiles; for example, the anthelmintics category includes albendazole, ivermectin, and mebendazole, while antibiotics include azithromycin and doxycycline, and antiprotozoals encompass meglumine, pentamidine, and suramin, each carrying specific cold chain, shelf life, and dosing considerations.
Distribution channel dynamics further influence access and uptake, with government programs, hospital pharmacies, NGO distribution networks, and retail pharmacies each requiring tailored logistics and financing mechanisms. End users such as clinics, community health centers, hospitals, and mobile camps differ in human resources, diagnostic capacity, and patient throughput, shaping the selection of formulations and administration routes. Oral, parenteral, and topical routes of administration create varying requirements for training, waste management, and patient adherence. Finally, the choice between mass drug administration and targeted therapy reflects divergent surveillance needs, community engagement strategies, and monitoring frameworks. Taken together, these segmentation lenses highlight the necessity of integrated planning that reconciles clinical efficacy with distribution feasibility and community context
Actionable regional insights that reconcile manufacturing capacities, regulatory variability, and distribution constraints across global territories
Regional dynamics materially condition how treatment strategies are designed and implemented, with distinct operational realities across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, health systems exhibit a mix of robust urban facilities and remote rural service gaps, requiring flexible distribution that can bridge centralized procurement with last-mile delivery to community health centers and mobile camps. Regulatory frameworks are heterogeneous across the region, which necessitates adaptive registration and supply strategies for imported therapeutics.
In Europe Middle East & Africa, the continent and its adjacent regions present wide variability in manufacturing capacity, donor engagement, and infrastructural resilience, prompting a focus on localized production, capacity building, and innovative financing. This region often presents the highest operational constraints, which increases the importance of public-private partnerships and NGO coordination to maintain continuous treatment delivery. Meanwhile, Asia-Pacific combines high-volume manufacturing hubs with complex intra-regional trade dynamics, enabling opportunities for API sourcing and contract manufacturing while also encountering challenges related to regulatory convergence and transport logistics.
Across all regions, stakeholders must reconcile regional policy environments, procurement norms, and field-level delivery constraints. Therefore, regional strategies should emphasize capacity strengthening, regulatory alignment where feasible, and collaborative procurement mechanisms that reduce friction and foster predictable supply for critical therapies
In-depth corporate insights revealing how manufacturing depth, strategic partnerships, and digital supply chain capabilities determine competitive positioning and program impact
The competitive and collaborative dynamics among manufacturers, contract development and manufacturing organizations, non-governmental implementers, and technology providers are reshaping how treatments reach patients. Leading manufacturers with integrated API capabilities and diversified production footprints are better positioned to absorb trade disruptions and scale mass drug administration campaigns, while smaller generic producers and specialized suppliers often compete on agility and cost efficiency. Contract manufacturing relationships are increasingly strategic rather than transactional, with long-term capacity partnerships that enable technology transfer and localized production.
Non-profit partners and global health implementers play a pivotal role in demand aggregation and distribution, often bridging financing gaps and operational complexity for government-led programs. Meanwhile, technology firms offering digital supply chain solutions and data analytics are becoming essential collaborators by improving forecasting accuracy and enabling more targeted therapy deployment. In this environment, successful companies combine manufacturing reliability with flexible commercial models, transparent compliance practices, and proactive engagement in public-private partnerships.
Ultimately, portfolio diversification, investment in quality management systems, and participation in pooled procurement or regional manufacturing initiatives distinguish market leaders from followers. Firms that invest in regulatory readiness and community-centered delivery models will be better positioned to partner with funders and ministries of health to sustain long-term treatment programs
Actionable recommendations that combine immediate supply resilience measures with long-term investments in regional capacity building and programmatic efficiency
Industry leaders should prioritize a set of practical actions that balance immediate operational needs with durable capacity building. First, strengthen supplier diversification and contractual flexibility to manage tariff-induced cost volatility and logistical disruptions, while simultaneously investing in regional manufacturing pilot programs and technology transfer agreements that reduce long-term import dependence. Second, align product portfolios with end-user capacities by favoring formulations and administration routes that minimize cold chain burdens and simplify training requirements for clinic and community health staff.
Third, leverage public-private partnerships and pooled procurement mechanisms to aggregate demand, negotiate better supply terms, and share risk across stakeholders. Fourth, integrate digital tools for inventory management and geospatial targeting to improve the precision of mass drug administration and targeted therapy initiatives, thereby increasing program efficiency and minimizing waste. Fifth, engage proactively with regulators and donors to accelerate registration pathways and align funding cycles with procurement realities.
Finally, invest in monitoring and evaluation frameworks that capture not only coverage but also treatment effectiveness, adherence, and community acceptance. By adopting these recommendations, leaders can create resilient, responsive treatment programs that withstand trade shocks and evolving epidemiological patterns while centering patient outcomes
Transparent multi-method research methodology combining stakeholder interviews, field case studies, regulatory analysis, and data triangulation to ensure robust insights
The research underpinning this report integrates multi-source qualitative and quantitative methods to ensure robust, defensible insights while maintaining transparency in assumptions and limitations. Primary research included structured interviews with stakeholders across the value chain, encompassing manufacturers, procurement specialists, program implementers, clinicians, and regulatory authorities to capture operational realities and strategic intent. These interviews were complemented by field-level observations and case study reviews that highlighted real-world delivery challenges in clinics, community health centers, hospitals, and mobile camps.
Secondary research involved systematic review of regulatory guidance, clinical literature, product dossiers, and logistics studies to contextualize programmatic implications for distinct formulations and routes of administration. Trade and policy analyses were incorporated to assess the downstream effects of tariff changes on procurement and manufacturing decisions. Data triangulation was applied throughout to validate findings across sources, and sensitivity checks were used to test the robustness of scenario narratives. Importantly, ethical research practices were observed during stakeholder engagements, ensuring confidentiality and informed consent where appropriate.
Readers should note methodological boundaries, including variability in data availability across regions and the dynamic nature of policy environments. Nevertheless, the methodological rigor provides a reliable foundation for strategic recommendations and operational planning
Conclusive synthesis emphasizing strategic urgency, coordinated action, and the need to align clinical efficacy with resilient delivery systems
In conclusion, neglected tropical disease treatment stands at an inflection point shaped by evolving scientific advances, shifting trade dynamics, and renewed emphasis on regional resilience. The landscape demands that stakeholders adopt multidimensional strategies that integrate procurement agility, localized manufacturing, and distribution models tailored to clinic and community realities. While tariff pressures and supply chain disruptions introduce immediate operational stresses, they also catalyze structural changes that can strengthen long-term program sustainability when addressed proactively.
Decision-makers must therefore act with both urgency and strategic foresight: focusing on supplier diversification and contractual innovation in the near term, while investing in capacity building, regulatory engagement, and technology-enabled delivery models for durable impact. Coordinated action across manufacturers, funders, implementers, and health authorities will accelerate the translation of evidence into equitable access to essential therapies.
Ultimately, the path forward requires blended solutions that reconcile clinical efficacy with pragmatic logistics, ensuring that interventions reach the people who need them most and that treatment programs remain resilient in the face of evolving geopolitical and economic forces
Please Note: PDF & Excel + Online Access - 1 Year
Comprehensive contextual introduction framing the clinical, programmatic, and supply chain imperatives that define neglected tropical disease treatment today
Neglected tropical diseases remain stubbornly prevalent across many low-resource settings, demanding renewed strategic focus from health systems, funders, and manufacturers alike. This introduction frames the current treatment landscape, emphasizing the complex interplay of clinical needs, programmatic delivery, and supply chain constraints that shape patient access to essential interventions. It acknowledges the progress achieved through mass drug administration campaigns and targeted therapies while also underscoring persistent gaps in coverage, diagnostics, and sustainable manufacturing capacity.
Drawing on recent regulatory shifts, partnerships between public and private stakeholders, and evolving donor priorities, the narrative situates stakeholders at the intersection of opportunity and urgency. Consequently, health leaders must reconcile short-term operational pressures with long-term investments in local capacity building. In particular, procurement teams and program managers need evidence-based guidance that aligns clinical protocols with distribution realities, including the logistical demands of reaching remote clinics, community health centers, mobile camps, and hospital settings.
Overall, the introduction sets a pragmatic tone: it invites multidisciplinary collaboration, highlights actionable entry points for strengthening treatment delivery, and prepares readers for deeper analysis of structural shifts, tariff-driven disruptions, and segmentation-specific implications in the sections that follow
Transformative shifts in diagnostics, partnerships, regulatory harmonization, and delivery models that are redefining neglected tropical disease treatment paradigms
The treatment landscape for neglected tropical diseases is undergoing decisive transformation as new scientific, policy, and operational forces converge. Advances in diagnostics and drug development are refining treatment algorithms, while digital health tools and geospatial analytics are allowing program managers to target interventions more precisely. Simultaneously, regulatory harmonization efforts and accelerated approval pathways are reducing time to deployment for critical therapies, enabling faster translation of research into practice.
Institutional shifts are likewise reshaping funding models and partnership structures. Donor portfolios increasingly prioritize integrated health platforms that bundle NTD interventions with broader primary care services, which in turn affects procurement strategies and distribution planning. Public-private collaborations are scaling up technology transfers and local manufacturing pilots, responding to the dual pressures of supply security and cost containment. As a result, traditional models of centralized mass drug administration are adapting to incorporate more targeted therapy approaches in settings where surveillance data justify differentiated responses.
Taken together, these transformative shifts underscore a move from one-size-fits-all campaigns toward adaptive, evidence-driven programs. Stakeholders must therefore pivot to agile operational frameworks that combine clinical efficacy with resilient supply chains and community-centered delivery models to sustain long-term impact
Cumulative global supply chain and procurement consequences stemming from new tariff measures introduced in the United States and their operational ripple effects
The introduction of new tariff measures in the United States during 2025 has produced a ripple effect across global supply chains that serve neglected tropical disease treatment programs. In practical terms, higher import tariffs on pharmaceutical inputs and finished products have elevated landed costs for manufacturers and procurers that rely on transnational APIs and finished-dose manufacturing. This has prompted urgency among program managers and procurement teams to reassess sourcing strategies and to prioritize supply chain redundancy and transparency.
Consequently, manufacturers and contract production organizations are accelerating conversations around nearshoring and regional manufacturing hubs to mitigate tariff exposure and transportation bottlenecks. These shifts have direct implications for procurement timelines, as lead times lengthen when new supplier qualification and regulatory compliance processes are required. In addition, civil society organizations and humanitarian procurers face tighter budgeting constraints that complicate the planning of large-scale distribution efforts.
Moreover, the tariff environment has catalyzed a renewed emphasis on partnerships that de-risk supply continuity. Strategic responses have included coordinated pooled procurement, supplier diversification, and contractual mechanisms that share tariff-related cost volatility across stakeholders. While this restructuring introduces short-term operational friction, it also creates opportunities to build more resilient, regionally anchored manufacturing and distribution models that can sustain treatment programs under evolving trade regimes
Rich segmentation-driven insights that align disease-specific clinical needs with formulation, distribution channel capacity, end-user realities, and treatment strategies
Segment-specific analysis reveals differentiated implications across therapeutic indications, drug classes, distribution channels, end-user settings, routes of administration, and treatment approaches. Based on disease indication, the landscape varies between vector-borne viral diseases like dengue and parasitic infections such as lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma, with each disease presenting unique clinical requirements and programmatic delivery challenges. Treatment modalities diverge materially when considering drug type, where anthelmintics, antiarthropodals, antibiotics, antiprotozoals, and insecticides occupy distinct development, procurement, and storage profiles; for example, the anthelmintics category includes albendazole, ivermectin, and mebendazole, while antibiotics include azithromycin and doxycycline, and antiprotozoals encompass meglumine, pentamidine, and suramin, each carrying specific cold chain, shelf life, and dosing considerations.
Distribution channel dynamics further influence access and uptake, with government programs, hospital pharmacies, NGO distribution networks, and retail pharmacies each requiring tailored logistics and financing mechanisms. End users such as clinics, community health centers, hospitals, and mobile camps differ in human resources, diagnostic capacity, and patient throughput, shaping the selection of formulations and administration routes. Oral, parenteral, and topical routes of administration create varying requirements for training, waste management, and patient adherence. Finally, the choice between mass drug administration and targeted therapy reflects divergent surveillance needs, community engagement strategies, and monitoring frameworks. Taken together, these segmentation lenses highlight the necessity of integrated planning that reconciles clinical efficacy with distribution feasibility and community context
Actionable regional insights that reconcile manufacturing capacities, regulatory variability, and distribution constraints across global territories
Regional dynamics materially condition how treatment strategies are designed and implemented, with distinct operational realities across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, health systems exhibit a mix of robust urban facilities and remote rural service gaps, requiring flexible distribution that can bridge centralized procurement with last-mile delivery to community health centers and mobile camps. Regulatory frameworks are heterogeneous across the region, which necessitates adaptive registration and supply strategies for imported therapeutics.
In Europe Middle East & Africa, the continent and its adjacent regions present wide variability in manufacturing capacity, donor engagement, and infrastructural resilience, prompting a focus on localized production, capacity building, and innovative financing. This region often presents the highest operational constraints, which increases the importance of public-private partnerships and NGO coordination to maintain continuous treatment delivery. Meanwhile, Asia-Pacific combines high-volume manufacturing hubs with complex intra-regional trade dynamics, enabling opportunities for API sourcing and contract manufacturing while also encountering challenges related to regulatory convergence and transport logistics.
Across all regions, stakeholders must reconcile regional policy environments, procurement norms, and field-level delivery constraints. Therefore, regional strategies should emphasize capacity strengthening, regulatory alignment where feasible, and collaborative procurement mechanisms that reduce friction and foster predictable supply for critical therapies
In-depth corporate insights revealing how manufacturing depth, strategic partnerships, and digital supply chain capabilities determine competitive positioning and program impact
The competitive and collaborative dynamics among manufacturers, contract development and manufacturing organizations, non-governmental implementers, and technology providers are reshaping how treatments reach patients. Leading manufacturers with integrated API capabilities and diversified production footprints are better positioned to absorb trade disruptions and scale mass drug administration campaigns, while smaller generic producers and specialized suppliers often compete on agility and cost efficiency. Contract manufacturing relationships are increasingly strategic rather than transactional, with long-term capacity partnerships that enable technology transfer and localized production.
Non-profit partners and global health implementers play a pivotal role in demand aggregation and distribution, often bridging financing gaps and operational complexity for government-led programs. Meanwhile, technology firms offering digital supply chain solutions and data analytics are becoming essential collaborators by improving forecasting accuracy and enabling more targeted therapy deployment. In this environment, successful companies combine manufacturing reliability with flexible commercial models, transparent compliance practices, and proactive engagement in public-private partnerships.
Ultimately, portfolio diversification, investment in quality management systems, and participation in pooled procurement or regional manufacturing initiatives distinguish market leaders from followers. Firms that invest in regulatory readiness and community-centered delivery models will be better positioned to partner with funders and ministries of health to sustain long-term treatment programs
Actionable recommendations that combine immediate supply resilience measures with long-term investments in regional capacity building and programmatic efficiency
Industry leaders should prioritize a set of practical actions that balance immediate operational needs with durable capacity building. First, strengthen supplier diversification and contractual flexibility to manage tariff-induced cost volatility and logistical disruptions, while simultaneously investing in regional manufacturing pilot programs and technology transfer agreements that reduce long-term import dependence. Second, align product portfolios with end-user capacities by favoring formulations and administration routes that minimize cold chain burdens and simplify training requirements for clinic and community health staff.
Third, leverage public-private partnerships and pooled procurement mechanisms to aggregate demand, negotiate better supply terms, and share risk across stakeholders. Fourth, integrate digital tools for inventory management and geospatial targeting to improve the precision of mass drug administration and targeted therapy initiatives, thereby increasing program efficiency and minimizing waste. Fifth, engage proactively with regulators and donors to accelerate registration pathways and align funding cycles with procurement realities.
Finally, invest in monitoring and evaluation frameworks that capture not only coverage but also treatment effectiveness, adherence, and community acceptance. By adopting these recommendations, leaders can create resilient, responsive treatment programs that withstand trade shocks and evolving epidemiological patterns while centering patient outcomes
Transparent multi-method research methodology combining stakeholder interviews, field case studies, regulatory analysis, and data triangulation to ensure robust insights
The research underpinning this report integrates multi-source qualitative and quantitative methods to ensure robust, defensible insights while maintaining transparency in assumptions and limitations. Primary research included structured interviews with stakeholders across the value chain, encompassing manufacturers, procurement specialists, program implementers, clinicians, and regulatory authorities to capture operational realities and strategic intent. These interviews were complemented by field-level observations and case study reviews that highlighted real-world delivery challenges in clinics, community health centers, hospitals, and mobile camps.
Secondary research involved systematic review of regulatory guidance, clinical literature, product dossiers, and logistics studies to contextualize programmatic implications for distinct formulations and routes of administration. Trade and policy analyses were incorporated to assess the downstream effects of tariff changes on procurement and manufacturing decisions. Data triangulation was applied throughout to validate findings across sources, and sensitivity checks were used to test the robustness of scenario narratives. Importantly, ethical research practices were observed during stakeholder engagements, ensuring confidentiality and informed consent where appropriate.
Readers should note methodological boundaries, including variability in data availability across regions and the dynamic nature of policy environments. Nevertheless, the methodological rigor provides a reliable foundation for strategic recommendations and operational planning
Conclusive synthesis emphasizing strategic urgency, coordinated action, and the need to align clinical efficacy with resilient delivery systems
In conclusion, neglected tropical disease treatment stands at an inflection point shaped by evolving scientific advances, shifting trade dynamics, and renewed emphasis on regional resilience. The landscape demands that stakeholders adopt multidimensional strategies that integrate procurement agility, localized manufacturing, and distribution models tailored to clinic and community realities. While tariff pressures and supply chain disruptions introduce immediate operational stresses, they also catalyze structural changes that can strengthen long-term program sustainability when addressed proactively.
Decision-makers must therefore act with both urgency and strategic foresight: focusing on supplier diversification and contractual innovation in the near term, while investing in capacity building, regulatory engagement, and technology-enabled delivery models for durable impact. Coordinated action across manufacturers, funders, implementers, and health authorities will accelerate the translation of evidence into equitable access to essential therapies.
Ultimately, the path forward requires blended solutions that reconcile clinical efficacy with pragmatic logistics, ensuring that interventions reach the people who need them most and that treatment programs remain resilient in the face of evolving geopolitical and economic forces
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
188 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Expansion of public–private partnerships for R&D acceleration in neglected tropical disease drug development
- 5.2. Integration of smartphone-enabled rapid diagnostic testing into community control programs for schistosomiasis
- 5.3. Adoption of mRNA vaccine platforms for novel immunization strategies against visceral leishmaniasis in endemic regions
- 5.4. Implementation of digital supply chain management solutions to optimize last-mile distribution of neglected tropical disease treatments
- 5.5. Surge in philanthropic and impact investment funding for combination therapies targeting cutaneous leishmaniasis
- 5.6. Fast-track regulatory approvals for novel macrocyclic lactone formulations addressing onchocerciasis drug resistance challenges
- 5.7. Deployment of AI-driven predictive modeling to enhance target identification in neglected tropical disease drug discovery pipelines
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Neglected Tropical Disease Treatment Market, by Drug Type
- 8.1. Anthelmintics
- 8.1.1. Albendazole
- 8.1.2. Ivermectin
- 8.1.3. Mebendazole
- 8.2. Antiarthropodals
- 8.3. Antibiotics
- 8.3.1. Azithromycin
- 8.3.2. Doxycycline
- 8.4. Antiprotozoals
- 8.4.1. Meglumine
- 8.4.2. Pentamidine
- 8.4.3. Suramin
- 8.5. Insecticides
- 9. Neglected Tropical Disease Treatment Market, by Disease Indication
- 9.1. Dengue
- 9.2. Lymphatic Filariasis
- 9.3. Onchocerciasis
- 9.4. Schistosomiasis
- 9.5. Trachoma
- 10. Neglected Tropical Disease Treatment Market, by Route Of Administration
- 10.1. Oral
- 10.2. Parenteral
- 10.3. Topical
- 11. Neglected Tropical Disease Treatment Market, by Treatment Approach
- 11.1. Mass Drug Administration
- 11.2. Targeted Therapy
- 12. Neglected Tropical Disease Treatment Market, by End User
- 12.1. Clinics
- 12.2. Community Health Centers
- 12.3. Hospitals
- 12.4. Mobile Camps
- 13. Neglected Tropical Disease Treatment Market, by Distribution Channel
- 13.1. Government Programs
- 13.2. Hospital Pharmacy
- 13.3. NGO Distribution
- 13.4. Retail Pharmacy
- 14. Neglected Tropical Disease Treatment Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Neglected Tropical Disease Treatment Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Neglected Tropical Disease Treatment Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. GlaxoSmithKline plc
- 17.3.2. Merck & Co., Inc.
- 17.3.3. Bayer AG
- 17.3.4. Novartis AG
- 17.3.5. Sanofi S.A.
- 17.3.6. Pfizer, Inc.
- 17.3.7. Eisai Co., Ltd.
- 17.3.8. Johnson & Johnson Services, Inc.
- 17.3.9. Takeda Pharmaceutical Company Limited
- 17.3.10. AbbVie Inc.
- 17.3.11. Astellas Pharma Inc.
- 17.3.12. AstraZeneca plc
- 17.3.13. Bristol‑Myers Squibb Company
- 17.3.14. Gilead Sciences, Inc.
- 17.3.15. Cipla Limited
- 17.3.16. Boehringer Ingelheim International GmbH
- 17.3.17. Serum Institute of India Pvt. Ltd.
- 17.3.18. Otsuka Pharmaceutical Co., Ltd.
- 17.3.19. Eli Lilly and Company
- 17.3.20. Sumitomo Dainippon Pharma Co., Ltd.
- 17.3.21. Hansa Biopharma AB
- 17.3.22. Amgen Inc.
- 17.3.23. Regeneron Pharmaceuticals, Inc.
- 17.3.24. Glenmark Pharmaceuticals Ltd.
- 17.3.25. Mylan N.V.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
